Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Invirase

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Medicinal Chemistry is often referred to as a mature science. We believe that this is a misperception. What is probably more… Expand
Highly Cited
2004
Highly Cited
2004
Saquinavir is a selective HIV protease inhibitor with limited systemic bioavailability (4% for the hard gelatin capsule (Invirase… Expand
Highly Cited
2002
Highly Cited
2002
AIMS Bioavailability of orally administered drugs depends on several factors including active excretion, e.g. by P-glycoprotein… Expand
2001
2001
Two studies, concerning the synthesis of original nucleoside analogs regarded as an application of heterochemistry on… Expand
  • figure 1
  • figure 2
Review
1998
Review
1998
Cytochrome P450 3A4 (CYP3A4), the major phase I drug metabolizing enzyme in humans, and the MDR1 gene product P-glycoprotein (P… Expand
1997
1997
The humoral immune response to HIV infection plays an important role in determining disease progression. Few and discordant… Expand
1996
1996
  • MMWR. Morbidity and mortality weekly report
  • 1996
  • Corpus ID: 25134566
In 1995 and 1996, the Food and Drug Administration (FDA) approved three products in the new protease inhibitor class of drugs… Expand
1996
1996
  • G. Folkers
  • NIAID AIDS agenda
  • 1996
  • Corpus ID: 28251693
The Food and Drug Administration (FDA) approved two new protease inhibitors--ritonavir and indinavir--for the treatment of HIV… Expand
1995
1995
  • J. James
  • AIDS treatment news
  • 1995
  • Corpus ID: 42637469
Saquinavir, developed by Hoffmann-LaRoche under the trade name Invirase, is the first protease inhibitor to be approved by the… Expand
1995
1995
: Saquinavir, developed by Hoffmann-LaRoche under the trade name Invirase, is the first protease inhibitor to be approved by the… Expand